Hemas Holdings Ltd. · CSELK:HHL.N0000
Hemas — Q4 & FY2026 Earnings Presentation
20 slides from Hemas's earnings presentation, June 2026
Slide 1: Earnings Call Presentation - Q4 & Full Year FY26
Q4 & Full Year FY26 Page 1 Earnings Call Presentation- Q4 & Full Year FY26 June 2026
Slide 2: Index
INDEX Q4 & Full Year FY26 Page 2 Q4 & FULL YEAR SHARE SECTOR SUSTAINABILITY STRATEGY & Q&A FY26 FINANCIAL PERFORMANCE PERFORMANCE REVIEW OUTLOOK SEGMENT RESULTS
Slide 3: Financial Results: 12m Performance FY26 vs FY25
FINANCIAL RESULTS Q4 & Full Year FY26 12m Performance FY26 vs FY25 Page 3 REVENUE GP NET Reduction in net gearing reflects LKR Mn MARGIN Revenue growth was largely led by GEARING the quality of cash generation , it volume growth while tight input RATIO gives HHL optionality to pursue FY26 FY26 cost
Slide 4: Financial Results: 3m Performance Q4 FY26 vs Q4 FY25
FINANCIAL RESULTS Q4 & Full Year FY26 3m Performance Q4 FY26 vs Q4 FY25 Page 4 REVENUE GP GP margin grew largely on LKR Mn MARGIN disciplined management of input. HCB SL, Q4’s largest contributor Q4 FY26 Q4 FY26 to revenue growth had a marginal 31,540 34.5% price growth but nearly 15% volume growth.
Slide 5: Momentum in Share Performance
MOMENTUM IN SHARE PERFORMANCE Compared against Market Q4 & Full Year FY26 Page 5 YoY Growth in Index (%) 54.2% HHL ASPI FY24 FY25 FY26 49.3% HHL TSR ASTRI 46.4% Price to Earnings 7.9x 8.9x 9.9x 39.2% 38.2% 37.3% 35.7% 33.2% 31.6% 31.3% Market Capitalisation 27.3% 27.3% 26.9% 47,972 71,677 88,681 (LK
Slide 6: Sector Performance Summary: 12m FY26 vs FY25
SECTOR PERFORMANCE SUMMARY Q4 & Full Year FY26 12m Performance FY26 vs FY25 Page 6 Revenue Walk (LKR Mn) EBITDA Walk (LKR Mn) Earnings Walk (LKR Mn) 67 346 127,362 1,039 5 1,029 8,021 (4) 16,449 (367) 327 49 8,921 (122) 609 117,970 15,705 8,057 Consumer Consumer Consumer FY25 Healthcare Mobility Oth
Slide 7: Sector Performance Summary: Q4 FY26 vs Q4 FY25
SECTOR PERFORMANCE SUMMARY Q4 & Full Year FY26 3m Performance Q4 FY26 vs Q4 FY25 Page 7 Revenue Walk (LKR Mn) EBITDA Walk (LKR Mn) Earnings Walk (LKR Mn) 76 31,540 458 (3) 663 204 (2) 4,915 30,347 432 (117) 94 3,030 256 (40) 4,398 144 2,576 Q4 Consumer Q4 Q4 Consumer Q4 Q4 Consumer Q4 Healthcare Mob
Slide 8: Consumer Brands
CONSUMER BRANDS Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 8 Revenue (LKR Mn) Full year, all segments grew 45,998 47,027 volumes. 4.5% 2.2% Q4 revenue growth was led 10,087 10,545 by double digit volume #1 Baby Care growth in Home and Q4 FY25 Q4 FY26 FY25 FY26 Personal Ca
Slide 9: Consumer Brands: Home and Personal Care – Sri Lanka & International
CONSUME BRANDS: HOME AND PERSONAL CARE – SRI LANKA & INTERNATIONAL Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 9 Revenue Home and Personal Care – Sri Lanka and International (LKR Mn) 4.0% 31,467 Q4 FY25 Q4 FY26 YoY FY25 FY26 YoY 30,270 GP margin 43.3% 46.7% 3.5% 44.1% 44.6
Slide 10: Consumer Brands: Learning
CONSUMER BRANDS: LEARNING Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 10 Revenue Learning (LKR Mn) 15,728 15,559 Q4 FY25 Q4 FY26 YoY FY25 FY26 YoY GP margin 35.0% 32.1% (2.9%) 36.7% 38.5% 1.8% (32.2%) (1.1%) EBITDA margin 14.3% (1.8%) (16.2%) 19.1% 18.1% (0.9%) 2,757 1,870
Slide 11: Healthcare
HEALTHCARE Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 11 Revenue (LKR Mn) All segments saw revenue 78,009 69,987 growth and GP margin expansion in FY26. 3.4% 11.5% 19,746 20,409 Q4 FY25 Q4 FY26 FY25 FY26 EBITDA (LKR Mn) EBITDA margin expanded 8,633 7,594 over 1% in Q4 and
Slide 12: Healthcare: Pharmaceutical
HEALTHCARE: PHARMACEUTICAL Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 12 Revenue Pharma Manufacturing & Distribution (LKR Mn) 67,071 Q4 FY25 Q4 FY26 YoY FY25 FY26 YoY 61,183 GP margin 18.6% 22.0% 3.4% 17.8% 18.5% 0.7% 1.3% 9.6% EBITDA margin 11.0% 13.5% 2.5% 9.7% 9.9% 0.2
Slide 13: Healthcare: Hospitals
HEALTHCARE: HOSPITALS Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 13 Revenue Hospitals (LKR Mn) 24.2% Q4 FY25 Q4 FY26 YoY FY25 FY26 YoY 10,938 8,804 GP margin 49.9% 49.8% (0.1%) 47.4% 48.6% 1.2% 18.8% EBITDA margin 21.2% 16.5% (4.7%) 19.0% 18.3% (0.7%) 2,312 2,747 Earnings
Slide 14: Mobility
MOBILITY Performance Review (Q4 FY26 & FY26 Full Year) Q4 & Full Year FY26 Page 14 Revenue Maritime (LKR Mn) Aviation (Forbes Air Services) 17.8% (Evergreen) 2,293 YoY 1,947 Passenger Pax TEUs Growth Cargo Growth Growth 15.6% Q4 FY26 44.4% (18.0%) (27.2%) 487 563 FY26 34.9% 6.4% (0.9%) Q4 FY25 Q4 FY
Slide 15: Sustainability
SUSTAINABILITY Q4 & Full Year FY26 Page 15 SOCIAL IMPACT: 143,100+ INDIVIDUALS EMPOWERED ENVIRONMENTAL AGENDA & IMPACT Creating Equal Opportunities for Learning FY26 Update 2030 GOAL 59,900+ Children and Teachers ▪ Creating quality educational experiences for every child. 50% Facilitate the collecti
Slide 16: Awards and Recognitions
AWARDS AND RECOGNITIONS 80+ Awards and Recognitions Q4 & Full Year FY26 Page 16 One of 200 Sri Lanka’s Top 10 National Best Sri Lanka’s top three corporate citizens at Best Under a Billion Employers at the Inaugural National the Best Corporate Citizen Sustainability Companies for 2025 Best Employer
Slide 17: Macro Economic Factors & Impact on HHL
MACRO ECONOMIC FACTORS & IMPACT ON HHL Q4 & Full Year FY26 Page 17 Middle East War and Impact Rising interest rates Current net cash position will mitigate financing costs that will come through as we expand. Impact will be passed through via price adjustments. LKR depreciation FY21 FY22 FY23 FY24 F
Slide 18: Businesses within Portfolio Role
PORTFOLIO ROLE Reason our results look the way it is (some generating current returns and others being built for the future)… Q4 & Full Year FY26 Page 18 Core Value Generators Innovation & Expansion Catalysts New Growth Engines Cash cows & efficiency leaders New products, Unmet needs Growth markets
Slide 19: Q & A Segment
Q4 & Full Year FY26 Page 19 Q & A Segment
Slide 20: Disclaimer
Q4 & Full Year FY26 Page 20 Disclaimer The material in this presentation has been prepared by Hemas Holdings PLC (“Hemas”) and is general background information about Hemas’ activities current as at the date of this presentation. This information is given in summary form and does not purport to be c